Tafalgie Therapeutics
- Biotech or pharma, therapeutic R&D
Tafalgie Therapeutics is targeting the $100 billion pain market by 2030 by introducing a groundbreaking first-in-class of highly effective, non-addictive, non-opioid analgesics with an excellent safety profile. It features a new mode of action with several mechanism that reduce the intensity of acute and chronic pain, as well as a novel preventive effect. The company’s mission is to address the urgent need for effective pain management, through treatments that significantly improve patient outcomes in the current context of the opioid crisis and a rising prevalence of chronic pain. In a global market with an ageing pharmacopeia awaiting effective alternative solutions, Tafalgie’s project has the potential to become a global blockbuster in a single market momentum. The strategy is focused on drug development through late-stage clinical trials, followed by partnership and licensing agreement with major Big Pharma.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}